• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Successful treatment of recalcitrant cutaneous lupus erythematosus with anifrolumab in patients without systemic lupus erythematosus.

作者信息

Abdelmalik Bishoy, Svoboda Steven, Gurnani Pooja, Motaparthi Kiran

机构信息

University of Florida College of Medicine, Gainesville, Florida.

Department of Dermatology, University of Florida College of Medicine, Gainesville, Florida.

出版信息

JAAD Case Rep. 2024 Nov 24;55:57-61. doi: 10.1016/j.jdcr.2024.11.014. eCollection 2025 Jan.

DOI:10.1016/j.jdcr.2024.11.014
PMID:39802940
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11722611/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9155/11722611/ca6c70abf8d6/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9155/11722611/db43d68158dc/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9155/11722611/da6bef61e3b2/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9155/11722611/26ed24f7a6bb/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9155/11722611/b9e6688b2255/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9155/11722611/cfaf8ca649ec/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9155/11722611/ca6c70abf8d6/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9155/11722611/db43d68158dc/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9155/11722611/da6bef61e3b2/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9155/11722611/26ed24f7a6bb/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9155/11722611/b9e6688b2255/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9155/11722611/cfaf8ca649ec/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9155/11722611/ca6c70abf8d6/gr6.jpg

相似文献

1
Successful treatment of recalcitrant cutaneous lupus erythematosus with anifrolumab in patients without systemic lupus erythematosus.在无系统性红斑狼疮的患者中使用阿尼鲁单抗成功治疗顽固性皮肤红斑狼疮。
JAAD Case Rep. 2024 Nov 24;55:57-61. doi: 10.1016/j.jdcr.2024.11.014. eCollection 2025 Jan.
2
Case series of anifrolumab for treatment of cutaneous lupus erythematosus and lupus-related mucocutaneous manifestations in patients with SLE.系统性红斑狼疮患者用阿尼鲁单抗治疗红斑狼疮皮疹和狼疮相关黏膜表现的病例系列
Lupus Sci Med. 2023 Dec 19;10(2):e001007. doi: 10.1136/lupus-2023-001007.
3
Anifrolumab for refractory cutaneous lupus lesions in pediatric systemic lupus erythematosus.阿尼鲁单抗用于治疗儿童系统性红斑狼疮的难治性皮肤狼疮病变。
Lupus. 2025 Apr;34(5):533-536. doi: 10.1177/09612033251330094. Epub 2025 Mar 23.
4
Anifrolumab for systemic lupus erythematosus with multi-refractory skin disease: A case series of 18 patients.阿尼鲁单抗治疗多药难治性皮肤疾病的系统性红斑狼疮：18 例患者的病例系列研究。
Lupus. 2024 Oct;33(11):1248-1253. doi: 10.1177/09612033241273023. Epub 2024 Aug 4.
5
Rapid efficacy of anifrolumab across multiple subtypes of recalcitrant cutaneous lupus erythematosus parallels changes in discrete subsets of blood transcriptomic and cellular biomarkers.阿尼鲁单抗在多种难治性皮肤红斑狼疮亚型中的快速疗效与血液转录组和细胞生物标志物离散亚群的变化平行。
Br J Dermatol. 2023 Jul 17;189(2):210-218. doi: 10.1093/bjd/ljad089.
6
Role of Anifrolumab in Refractory Cutaneous Manifestations of Lupus Erythematosus: A Case Series and Literature Review.阿尼鲁单抗在红斑狼疮难治性皮肤表现中的作用：病例系列及文献综述
Cureus. 2023 May 27;15(5):e39553. doi: 10.7759/cureus.39553. eCollection 2023 May.
7
Anifrolumab for treatment of refractory cutaneous lupus erythematosus.阿尼鲁单抗治疗难治性皮肤红斑狼疮。
Clin Exp Dermatol. 2022 Nov;47(11):1998-2001. doi: 10.1111/ced.15335. Epub 2022 Aug 26.
8
[Translated article] Use of Anifrolumab in Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus, and Other Autoimmune Dermatoses.[翻译文章] 阿尼鲁单抗在系统性红斑狼疮、皮肤型红斑狼疮及其他自身免疫性皮肤病中的应用
Actas Dermosifiliogr. 2025 Jan;116(1):T55-T67. doi: 10.1016/j.ad.2024.10.008. Epub 2024 Oct 9.
9
Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.阿尼鲁单抗用于狼疮的干扰素抑制：对导致美国食品药品监督管理局批准的证据的批判性评估。
ACR Open Rheumatol. 2022 Jun;4(6):486-491. doi: 10.1002/acr2.11414. Epub 2022 Feb 14.
10
Rapid Response of Refractory Systemic Lupus Erythematosus Skin Manifestations to Anifrolumab-A Case-Based Review of Clinical Trial Data Suggesting a Domain-Based Therapeutic Approach.难治性系统性红斑狼疮皮肤表现对阿尼鲁单抗的快速反应——基于病例的临床试验数据综述，提示基于领域的治疗方法
J Clin Med. 2022 Jun 15;11(12):3449. doi: 10.3390/jcm11123449.

引用本文的文献

1
Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Afimetoran, a Toll-Like Receptor 7 and 8 Inhibitor, in Patients With Cutaneous Lupus Erythematosus: A Phase 1b Randomized, Double-Blind, Placebo-Controlled Study.Toll样受体7和8抑制剂阿菲美托兰在皮肤红斑狼疮患者中的安全性、耐受性、疗效、药代动力学及药效学：一项1b期随机、双盲、安慰剂对照研究
ACR Open Rheumatol. 2025 Jul;7(7):e70059. doi: 10.1002/acr2.70059.

本文引用的文献

1
Case series of anifrolumab for treatment of cutaneous lupus erythematosus and lupus-related mucocutaneous manifestations in patients with SLE.系统性红斑狼疮患者用阿尼鲁单抗治疗红斑狼疮皮疹和狼疮相关黏膜表现的病例系列
Lupus Sci Med. 2023 Dec 19;10(2):e001007. doi: 10.1136/lupus-2023-001007.
2
Case Report: Response of cutaneous lupus lesions in SLE to interferon receptor blockade parallels reduction of interferon score in blood.病例报告：SLE 患者皮肤狼疮病变对干扰素受体阻断的反应与血液中干扰素评分的降低呈平行关系。
Front Immunol. 2023 Sep 21;14:1253279. doi: 10.3389/fimmu.2023.1253279. eCollection 2023.
3
Successful treatment of severe chronic cutaneous lupus with anifrolumab: A series of 6 cases.
用阿尼氟单抗成功治疗重度慢性皮肤型狼疮：6例病例系列
JAAD Case Rep. 2023 May 4;37:21-29. doi: 10.1016/j.jdcr.2023.04.024. eCollection 2023 Jul.
4
Rapid efficacy of anifrolumab in refractory cutaneous lupus erythematosus.阿尼氟单抗治疗难治性皮肤红斑狼疮的快速疗效
J Am Acad Dermatol. 2023 Jul;89(1):171-173. doi: 10.1016/j.jaad.2023.02.044. Epub 2023 Mar 5.
5
A Randomized, Placebo-Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus.一项评估阿尼鲁单抗在活跃系统性红斑狼疮患者中长期安全性和耐受性的随机、安慰剂对照 III 期扩展试验。
Arthritis Rheumatol. 2023 Feb;75(2):253-265. doi: 10.1002/art.42392. Epub 2022 Nov 11.
6
Cutaneous Involvement in Systemic Lupus Erythematosus: A Review for the Rheumatologist.系统性红斑狼疮的皮肤表现：风湿病医生的综述。
J Rheumatol. 2023 Jan;50(1):27-35. doi: 10.3899/jrheum.220089. Epub 2022 Sep 15.
7
Anifrolumab for treatment of refractory cutaneous lupus erythematosus.阿尼鲁单抗治疗难治性皮肤红斑狼疮。
Clin Exp Dermatol. 2022 Nov;47(11):1998-2001. doi: 10.1111/ced.15335. Epub 2022 Aug 26.
8
Treatment of cutaneous lupus erythematosus: current approaches and future strategies.治疗皮肤红斑狼疮：当前方法和未来策略。
Curr Opin Rheumatol. 2020 May;32(3):208-214. doi: 10.1097/BOR.0000000000000704.
9
Cutaneous lupus erythematosus: A review of the literature.皮肤型红斑狼疮：文献综述
Int J Womens Dermatol. 2019 Jul 31;5(5):320-329. doi: 10.1016/j.ijwd.2019.07.004. eCollection 2019 Dec.
10
Trial of Anifrolumab in Active Systemic Lupus Erythematosus.阿尼鲁单抗治疗活动性系统性红斑狼疮的试验。
N Engl J Med. 2020 Jan 16;382(3):211-221. doi: 10.1056/NEJMoa1912196. Epub 2019 Dec 18.